EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Advancing AADC deficiency therapy through MR-guided multisite delivery of AAV2-hAADC to dopaminergic and serotonergic pathways in the brainstem

Lluis Samaranch, Clemens Neudorfer, Matthew T Rocco, Allison O'Brien, Vikas Munjal, Nathan McFarland, Meika Travis, Anitvir S Taunque, Kaya E Ceyhan, Akhila Dandamudi, Ahmad Karkhah, Abigail Nimmo und 8 weitere

Molecular Therapy Advances · 2026-03 · 34 (1) · 201670

DOI: 10.1016/j.omta.2026.201670 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-03. Verfasst von Lluis Samaranch und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, National Institutes of Health, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare and often devastating neurometabolic disorder characterized by impaired synthesis of dopamine, serotonin, and norepinephrine. Affected children present with severe developmental delays, motor dysfunction, autonomic instability, and behavioral symptoms, and current treatments remain largely supportive. Current gene therapy trials for AADC deficiency have demonstrated the safety and tolerability of bilateral AAV2-hAADC infusion into the putamen or midbrain. These approaches have restored dopamine synthesis in the basal ganglia and the limbic systems. However, they have not affected serotonin levels, likely due to the lack of transduction of serotonergic neurons by inadequate coverage of relevant brainstem nuclei. Restoring serotonergic signaling may be critical for improving cognitive and behavioral outcomes, which are still not fully addressed by current dopamine-focused therapies. To address this limitation, we evaluated the safety of a multi-target, magnetic resonance (MR)-guided convection-enhanced delivery strategy in nonhuman primates, administering AAV2-AADC into serotonergic and noradrenergic nuclei in addition to current dopaminergic targets. This broader targeting approach aims to enhance serotonin modulation and restore neuromodulatory balance, with potential benefits for cognitive and behavioral function in children with AADC deficiency undergoing gene therapy.

Schlagwörter

Stichwörter der Autor:innen

AADC deficiencyAAV2-hAADCCEDconvection-enhanced deliverydopaminegene therapymonoamine metabolismmulti-target brain deliverynonhuman primatesserotonin

Autor:innen und Institutionen

  • Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA.
  • Gene Therapy Institute, The Ohio State University, Columbus, OH 43210, USA.
  • Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Medical Student Research Program, The Ohio State College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
  • Undergraduate Research Program, The Ohio State University, Columbus, OH 43210, USA.
  • Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH 43210, USA.

Förderung

  • NINDS NIH HHS
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Samaranch, L., Neudorfer, C., Rocco, M. T., O'Brien, A., Munjal, V., McFarland, N., Travis, M., Taunque, A. S., Ceyhan, K. E., Dandamudi, A., Karkhah, A., Nimmo, A., Bringas, J., Akhter, A. S., Youngblood, B., Mattox, L., Richardson, R. M., Forsayeth, J. R., Lonser, R. R., & Bankiewicz, K. S. (2026). Advancing AADC deficiency therapy through MR-guided multisite delivery of AAV2-hAADC to dopaminergic and serotonergic pathways in the brainstem. Molecular Therapy Advances, 34(1), 201670. https://doi.org/10.1016/j.omta.2026.201670

Vancouver

Samaranch L, Neudorfer C, Rocco MT, O'Brien A, Munjal V, McFarland N, et al. Advancing AADC deficiency therapy through MR-guided multisite delivery of AAV2-hAADC to dopaminergic and serotonergic pathways in the brainstem. Molecular Therapy Advances. 2026;34(1):201670. doi:10.1016/j.omta.2026.201670

BibTeX
@article{Samaranch2026,
  author = {Samaranch, Lluis and Neudorfer, Clemens and Rocco, Matthew T and O'Brien, Allison and Munjal, Vikas and McFarland, Nathan and Travis, Meika and Taunque, Anitvir S and Ceyhan, Kaya E and Dandamudi, Akhila and Karkhah, Ahmad and Nimmo, Abigail and Bringas, John and Akhter, Asad S and Youngblood, Brad and Mattox, Lori and Richardson, R Mark and Forsayeth, John R and Lonser, Russell R and Bankiewicz, Krystof S},
  title = {Advancing AADC deficiency therapy through MR-guided multisite delivery of AAV2-hAADC to dopaminergic and serotonergic pathways in the brainstem},
  journal = {Molecular Therapy Advances},
  year = {2026},
  volume = {34},
  number = {1},
  pages = {201670},
  doi = {10.1016/j.omta.2026.201670}
}
Kostenlos starten →